-
1
-
-
0000286732
-
A minute chromosome in human granulocytic leukemia
-
Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 142: 1497
-
(1960)
Science
, vol.142
, pp. 1497
-
-
Nowell, P.C.1
Hungerford, D.A.2
-
2
-
-
0033614446
-
Chronic myeloid leukemia
-
DOI 10.1056/NEJM199904293401706
-
Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40; PMID: 10219069; http://dx.doi.org/10.1056/NEJM199904293401706 (Pubitemid 29196596)
-
(1999)
New England Journal of Medicine
, vol.340
, Issue.17
, pp. 1330-1340
-
-
Sawyers, C.L.1
-
3
-
-
0031839231
-
The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells
-
Tauchi T, Okabe S, Miyazawa K, Ohyashiki K. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int J Oncol 1998; 12: 1269-76; PMID: 9592185 (Pubitemid 28239935)
-
(1998)
International Journal of Oncology
, vol.12
, Issue.6
, pp. 1269-1276
-
-
Tauchi, T.1
Okabe, S.2
Miyazawa, K.3
Ohyashiki, K.4
-
4
-
-
0029063970
-
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
-
PMID: 7606002
-
Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-36; PMID: 7606002
-
(1995)
Blood
, vol.86
, pp. 726-736
-
-
Skorski, T.1
Kanakaraj, P.2
Nieborowska-Skorska, M.3
Ratajczak, M.Z.4
Wen, S.C.5
Zon, G.6
Gewirtz, A.M.7
Perussia, B.8
Calabretta, B.9
-
5
-
-
0031573141
-
Constitutive Activation of JAKs and STATs in BCR-Abl-Expressing Cell Lines and Peripheral Blood Cells Derived from Leukemic Patients
-
Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159: 4720-8; PMID: 9366395 (Pubitemid 127471006)
-
(1997)
Journal of Immunology
, vol.159
, Issue.10
, pp. 4720-4728
-
-
Chai, S.K.1
Nichols, G.L.2
Rothman, P.3
-
6
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
DOI 10.1056/NEJM200104053441402
-
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42; PMID: 11287973; http://dx.doi.org/10.1056/NEJM200104053441402 (Pubitemid 32267973)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.14
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
7
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17; PMID: 17151364; http://dx.doi.org/10.1056/ NEJMoa062867 (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
8
-
-
33947224197
-
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
-
Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145: 913-23; PMID: 17179059; http://dx.doi.org/10.7326/0003- 4819-145-12-200612190-00008 (Pubitemid 351639967)
-
(2006)
Annals of Internal Medicine
, vol.145
, Issue.12
, pp. 913-923
-
-
Kantarjian, H.M.1
Talpaz, M.2
Giles, F.3
O'Brien, S.4
Cortes, J.5
-
9
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
DOI 10.1038/sj.leu.2402741
-
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-6; PMID: 12399961; http://dx.doi.org/10.1038/sj.leu.2402741 (Pubitemid 35331833)
-
(2002)
Leukemia
, vol.16
, Issue.11
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La Rosee, P.4
Muller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.P.9
Berger, U.10
Gschaidmeier, H.11
Druker, B.J.12
Hehlmann, R.13
-
10
-
-
73349122639
-
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
-
European LeukemiaNet PMID: 19884523
-
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-51; PMID: 19884523; http://dx.doi.org/10.1200/JCO.2009.25.0779
-
(2009)
J Clin Oncol
, vol.27
, pp. 6041-6051
-
-
Baccarani, M.1
Cortes, J.2
Pane, F.3
Niederwieser, D.4
Saglio, G.5
Apperley, J.6
Cervantes, F.7
Deininger, M.8
Gratwohl, A.9
Guilhot, F.10
-
11
-
-
73349100015
-
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up
-
PMID: 19729517
-
Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009; 114: 4361-8; PMID: 19729517; http://dx.doi.org/10.1182/blood-2009-05-221531
-
(2009)
Blood
, vol.114
, pp. 4361-4368
-
-
Garg, R.J.1
Kantarjian, H.2
O'Brien, S.3
Quintás-Cardama, A.4
Faderl, S.5
Estrov, Z.6
Cortes, J.7
-
12
-
-
65649102301
-
Firstline therapy for chronic myeloid leukemia: Past, present, and future
-
PMID: 19306355
-
Pavlovsky C, Kantarjian H, Cortes JE. Firstline therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009; 84: 287-93; PMID: 19306355; http://dx.doi.org/10.1002/ajh.21380
-
(2009)
Am J Hematol
, vol.84
, pp. 287-293
-
-
Pavlovsky, C.1
Kantarjian, H.2
Cortes, J.E.3
-
13
-
-
79952108609
-
AKT signaling in physiology and disease
-
PMID: 20549472
-
Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347: 105-33; PMID: 20549472; http://dx.doi.org/10. 1007/82-2010-66
-
(2010)
Curr Top Microbiol Immunol
, vol.347
, pp. 105-133
-
-
Vasudevan, K.M.1
Garraway, L.A.2
-
14
-
-
34247116441
-
Physiological roles of PKB/Akt isoforms in development and disease
-
DOI 10.1042/BST0350231
-
Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007; 35: 231-5; PMID: 17371246; http://dx.doi.org/10.1042/BST0350231 (Pubitemid 46596476)
-
(2007)
Biochemical Society Transactions
, vol.35
, Issue.2
, pp. 231-235
-
-
Dummler, B.1
Hemmings, B.A.2
-
15
-
-
2342565881
-
Advances in protein kinase B signalling: AKTion on multiple fronts
-
DOI 10.1016/j.tibs.2004.03.006, PII S096800040400074X
-
Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-42; PMID: 15130559; http://dx.doi.org/10.1016/j.tibs.2004.03.006 (Pubitemid 38591317)
-
(2004)
Trends in Biochemical Sciences
, vol.29
, Issue.5
, pp. 233-242
-
-
Brazil, D.P.1
Yang, Z.-Z.2
Hemmings, B.A.3
-
16
-
-
43049131769
-
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
-
PMID: 18166498
-
LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11: 32-50; PMID: 18166498; http://dx.doi.org/10.1016/j.drup. 2007.11.003
-
(2008)
Drug Resist Updat
, vol.11
, pp. 32-50
-
-
Lopiccolo, J.1
Blumenthal, G.M.2
Bernstein, W.B.3
Dennis, P.A.4
-
17
-
-
51049109033
-
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
-
PMID: 18606717
-
Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-63; PMID: 18606717; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1851-1863
-
-
Maira, S.M.1
Stauffer, F.2
Brueggen, J.3
Furet, P.4
Schnell, C.5
Fritsch, C.6
Brachmann, S.7
Chène, P.8
De Pover, A.9
Schoemaker, K.10
-
18
-
-
78751661556
-
Evolution of human BCRABL1 lymphoblastic leukaemia-initiating cells
-
PMID: 21248843
-
Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR, Dick JE. Evolution of human BCRABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-7; PMID: 21248843; http://dx.doi.org/10.1038/nature09733
-
(2011)
Nature
, vol.469
, pp. 362-367
-
-
Notta, F.1
Mullighan, C.G.2
Wang, J.C.3
Poeppl, A.4
Doulatov, S.5
Phillips, L.A.6
Ma, J.7
Minden, M.D.8
Downing, J.R.9
Dick, J.E.10
-
19
-
-
84872462658
-
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: Frequency and clonal relationships
-
PMID: 23223358
-
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013; 121: 489-98; PMID: 23223358; http://dx.doi.org/10.1182/blood-2012- 05-431379
-
(2013)
Blood
, vol.121
, pp. 489-498
-
-
Khorashad, J.S.1
Kelley, T.W.2
Szankasi, P.3
Mason, C.C.4
Soverini, S.5
Adrian, L.T.6
Eide, C.A.7
Zabriskie, M.S.8
Lange, T.9
Estrada, J.C.10
-
20
-
-
0034722888
-
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
-
DOI 10.1038/sj.onc.1204091
-
Hidalgo M, Rowinsky EK. The rapamycinsensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6; PMID: 11426655; http://dx.doi.org/10.1038/sj.onc.1204091 (Pubitemid 32197708)
-
(2000)
Oncogene
, vol.19
, Issue.56
, pp. 6680-6686
-
-
Hidalgo, M.1
Rowinsky, E.K.2
-
21
-
-
53049087363
-
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature: Implications for clinical imaging
-
PMID: 18701483
-
Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVPBEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68: 6598-607; PMID: 18701483; http://dx.doi.org/10.1158/0008-5472.CAN-08-1044
-
(2008)
Cancer Res
, vol.68
, pp. 6598-6607
-
-
Schnell, C.R.1
Stauffer, F.2
Allegrini, P.R.3
O'Reilly, T.4
McSheehy, P.M.5
Dartois, C.6
Stumm, M.7
Cozens, R.8
Littlewood-Evans, A.9
García-Echeverría, C.10
-
22
-
-
51849111524
-
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
-
PMID: 18829560
-
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-30; PMID: 18829560; http://dx.doi.org/10.1158/0008-5472.CAN-08-1385
-
(2008)
Cancer Res
, vol.68
, pp. 8022-8030
-
-
Serra, V.1
Markman, B.2
Scaltriti, M.3
Eichhorn, P.J.4
Valero, V.5
Guzman, M.6
Botero, M.L.7
Llonch, E.8
Atzori, F.9
Di Cosimo, S.10
-
23
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
PMID: 19029981
-
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6; PMID: 19029981; http://dx.doi.org/10.1038/nm.1890
-
(2008)
Nat Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
Crosby, K.4
Guimaraes, A.R.5
Upadhyay, R.6
Maira, M.7
McNamara, K.8
Perera, S.A.9
Song, Y.10
-
24
-
-
68849091778
-
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
-
PMID: 19671762
-
Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8: 2204-10; PMID: 19671762; http://dx.doi.org/10.1158/1535-7163.MCT-09-0160
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2204-2210
-
-
Liu, T.J.1
Koul, D.2
Lafortune, T.3
Tiao, N.4
Shen, R.J.5
Maira, S.M.6
Garcia-Echevrria, C.7
Yung, W.K.8
-
25
-
-
65949110376
-
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer
-
PMID: 19366795
-
Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69: 3955-62; PMID: 19366795; http://dx.doi.org/10.1158/0008-5472.CAN-08-4450
-
(2009)
Cancer Res
, vol.69
, pp. 3955-3962
-
-
Crowder, R.J.1
Phommaly, C.2
Tao, Y.3
Hoog, J.4
Luo, J.5
Perou, C.M.6
Parker, J.S.7
Miller, M.A.8
Huntsman, D.G.9
Lin, L.10
-
26
-
-
67650995912
-
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
-
PMID: 19584292
-
McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-42; PMID: 19584292; http://dx.doi.org/10.1158/0008-5472.CAN-08-4285
-
(2009)
Cancer Res
, vol.69
, pp. 5835-5842
-
-
McMillin, D.W.1
Ooi, M.2
Delmore, J.3
Negri, J.4
Hayden, P.5
Mitsiades, N.6
Jakubikova, J.7
Maira, S.M.8
Garcia-Echeverria, C.9
Schlossman, R.10
-
27
-
-
51649098950
-
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
-
PMID: 18548093
-
Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008; 22: 1728-36; PMID: 18548093; http://dx.doi.org/10.1038/leu.2008.158
-
(2008)
Leukemia
, vol.22
, pp. 1728-1736
-
-
Kojima, K.1
Shimanuki, M.2
Shikami, M.3
Samudio, I.J.4
Ruvolo, V.5
Corn, P.6
Hanaoka, N.7
Konopleva, M.8
Andreeff, M.9
Nakakuma, H.10
-
28
-
-
73349129405
-
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
-
PMID: 19850869
-
Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009; 106: 19503-8; PMID: 19850869; http://dx.doi.org/10. 1073/pnas.0905056106
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 19503-19508
-
-
Faber, A.C.1
Li, D.2
Song, Y.3
Liang, M.C.4
Yeap, B.Y.5
Bronson, R.T.6
Lifshits, E.7
Chen, Z.8
Maira, S.M.9
García-Echeverría, C.10
-
29
-
-
0037194613
-
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
-
DOI 10.1038/sj.onc.1205724
-
Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868-76; PMID: 12185586; http://dx.doi.org/10.1038/ sj.onc.1205724 (Pubitemid 35007237)
-
(2002)
Oncogene
, vol.21
, Issue.38
, pp. 5868-5876
-
-
Klejman, A.1
Rushen, L.2
Morrione, A.3
Slupianek, A.4
Skorski, T.5
-
30
-
-
37349090416
-
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
-
DOI 10.1111/j.1365-2362.2007.01892.x
-
Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstöcker M, Sperr WR, Pickl WF, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinibresistant chronic myeloid leukaemia. Eur J Clin Invest 2008; 38: 43-52; PMID: 18173550; http://dx.doi.org/10.1111/j.1365-2362.2007.01892.x (Pubitemid 350293855)
-
(2008)
European Journal of Clinical Investigation
, vol.38
, Issue.1
, pp. 43-52
-
-
Sillaber, C.1
Mayerhofer, M.2
Bohm, A.3
Vales, A.4
Gruze, A.5
Aichberger, K.J.6
Esterbauer, H.7
Pfeilstocker, M.8
Sperr, W.R.9
Pickl, W.F.10
Haas, O.A.11
Valent, P.12
-
31
-
-
28444479480
-
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
-
DOI 10.1182/blood-2005-06-2209
-
Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-54; PMID: 16105974; http://dx.doi.org/10.1182/ blood-2005-06-2209 (Pubitemid 41739036)
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3948-3954
-
-
Kimura, S.1
Naito, H.2
Segawa, H.3
Kuroda, J.4
Yuasa, T.5
Sato, K.6
Yokota, A.7
Kamitsuji, Y.8
Kawata, E.9
Ashihara, E.10
Nakaya, Y.11
Naruoka, H.12
Wakayama, T.13
Nasu, K.14
Asaki, T.15
Niwa, T.16
Hirabayashi, K.17
Maekawa, T.18
-
32
-
-
34247506325
-
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
-
DOI 10.1182/blood-2006-01-015347
-
Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011-5; PMID: 17303698; http://dx.doi.org/10.1182/blood-2006-01-015347 (Pubitemid 46827801)
-
(2007)
Blood
, vol.109
, Issue.11
, pp. 5011-5015
-
-
Ray, A.1
Cowan-Jacob, S.W.2
Manley, P.W.3
Mestan, J.4
Griffin, J.D.5
-
33
-
-
34347334539
-
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis
-
DOI 10.1089/scd.2007.9994
-
Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007; 16: 503-14; PMID: 17610380; http://dx.doi.org/10.1089/scd.2007.9994 (Pubitemid 47016235)
-
(2007)
Stem Cells and Development
, vol.16
, Issue.3
, pp. 503-514
-
-
Okabe, S.1
Tauchi, T.2
Nakajima, A.3
Sashida, G.4
Gotoh, A.5
Broxmeyer, H.E.6
Ohyashiki, J.H.7
Ohyashiki, K.8
-
34
-
-
84867763109
-
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCRABL- positive leukemia cells
-
PMID: 22642671
-
Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCRABL- positive leukemia cells. Stem Cells Dev 2012; 21: 2939-48; PMID: 22642671; http://dx.doi.org/10.1089/scd.2012.0016
-
(2012)
Stem Cells Dev
, vol.21
, pp. 2939-2948
-
-
Okabe, S.1
Tauchi, T.2
Tanaka, Y.3
Katagiri, S.4
Ohyashiki, K.5
|